BROS vs REGN · P/E 105, rev $1.28B vs P/E 14, rev $14.34B
Dutch Bros Inc (BROS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Dutch Bros Inc (BROS) is a restaurants company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported BROS revenue for 2024-12-31 was $1.28B. Net income was $66.5M. Revenue was up 32.6% from 2023-12-31 to 2024-12-31. BROS currently screens at market cap $11.74B and trailing P/E 105.0.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
BROS currently screens at market cap $11.74B and trailing P/E 105.0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the BROS and REGN stock pages for the full models.
Not investment advice.